Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma

Abstract

Objective: To develop a prediction model for long-term (≥5 years) disease-free survival (DFS) after the resection of pancreatic ductal adenocarcinoma (PDAC). Background: Despite high recurrence rates, ~10% of patients have long-term DFS after PDAC resection. A model to predict long-term DFS may aid individualized prognostication and shared decision-making. Methods: This nationwide cohort study included all consecutive patients who underwent PDAC resection in the Netherlands (2014–2016). The best-performing prognostic model was selected by Cox-proportional hazard analysis and Akaike’s Information Criterion, presented by hazard ratios (HRs) with 95% confidence intervals (CIs). Internal validation was performed, and discrimination and calibration indices were assessed. Results: In all, 836 patients with a median follow-up of 67 months (interquartile range 51–79) were analyzed. Long-term DFS was seen in 118 patients (14%). Factors predictive of long-term DFS were low preoperative carbohydrate antigen 19-9 (logarithmic; HR 1.21; 95% CI 1.10–1.32), no vascular resection (HR 1.33; 95% CI 1.12–1.58), T1 or T2 tumor stage (HR 1.52; 95% CI 1.14–2.04, and HR 1.17; 95% CI 0.98–1.39, respectively), well/moderate tumor differentiation (HR 1.44; 95% CI 1.22–1.68), absence of perineural and lymphovascular invasion (HR 1.42; 95% CI 1.11–1.81 and HR 1.14; 95% CI 0.96–1.36, respectively), N0 or N1 nodal status (HR 1.92; 95% CI 1.54–2.40, and HR 1.33; 95% CI 1.11–1.60, respectively), R0 resection margin status (HR 1.25; 95% CI 1.07–1.46), no major complications (HR 1.14; 95% CI 0.97–1.35) and adjuvant chemotherapy (HR 1.74; 95% CI 1.47–2.06). Moderate performance (concordance index 0.68) with adequate calibration (slope 0.99) was achieved. Conclusions: The developed prediction model, readily available at www.pancreascalculator.com, can be used to estimate the probability of long-term DFS after resection of pancreatic ductal adenocarcinoma.